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Abstract
Introduction
Sarcoma is a rare type of cancer. The incidence increases with age and elderly patients
may have comorbidity that affects the prognosis. The aim of this study was to describe the
type and prevalence of comorbidity in a nationwide population-based study in Denmark
from 2000–2013 and to analyse the impact of the different comorbidities on mortality.
Material and methods
The Danish Sarcoma Registry is a national clinical database containing all patients with sar-
coma in the extremities or trunk wall from 2000 and onwards. By linking data to other regis-
tries, we were able to get patient information on an individual level including date and cause
of death as well as the comorbidity type up to 10 years prior to the sarcoma diagnosis.
Based on diseases in the Charlson Comorbidity Index, we pooled the patients into six cate-
gories: no comorbidity, cardiopulmonary disease, gastrointestinal disease, neurovascular
disease, malignant neoplasms, and miscellaneous (diabetes, renal and connective tissue
diseases). 2167 patients were included.
Results
The prevalence of comorbidity was 20%. For patients with localized disease, comorbidity
increased the disease-specific mortality significantly (HR 1.70 (95% CI 1.36–2.13)). For
patients with metastatic disease at the time of diagnosis, comorbidity did not affect the dis-
ease-specific mortality (HR 1.05 (95% CI 0.78–1.42)). The presence of another cancer diag-
nosis within 10 years prior to the sarcoma diagnosis was the only significant independent
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prognostic factor of disease-specific mortality with an increase of 66% in mortality rate com-
pared to patients with no comorbidity (HR 1,66 (95% CI 1.22–2.25)).
Conclusion
Comorbidity is a strong independent prognostic factor of mortality in patients with localized
disease. This study emphasizes the need for optimizing the general health of comorbid
patients in order to achieve a survival benefit from treatment of patients with localized dis-
ease, as this is potentially modifiable.
Introduction
Sarcoma is a rare cancer that accounts for approximately 1% of newly diagnosed cancers in
Denmark [1,2]. Sarcomas occur in all age groups although the incidence increases with age [3–
5]. Due to a demographic shift towards a larger elderly population, more patients will require
treatment and follow-up in the future [6]. With increasing age, comorbidity will also be more
frequent and may affect prognosis in several ways: as an independent cause of death, by delay-
ing diagnosis, causing complications of treatment, or being the reason for less comprehensive
or aggressive treatment [6].
To improve the prognosis, additional knowledge of the sarcoma prognosis is needed, which
takes comorbidity into consideration. Studies have shown poorer survival among cancer
patients with comorbidity [7–14]. In general, the 5-year survival rates have improved among
cancer patients without comorbidity, but not among patients with severe comorbidity [12,15].
A recent single centre study from our group on soft tissue sarcoma patients, found that 25% of
the patients had comorbidity [16]. Presence of comorbidity was associated with significantly
increased overall and disease-specific mortality compared to soft tissue sarcoma patients with-
out comorbidity [16]. However, the study was limited to only soft tissue sarcoma patients in a
30 year time period, and there has been substantial progress in diagnosis, treatment and
pathology, thus more comprehensive studies are needed [17].
The aim of this study was to describe the type and prevalence of comorbidity in sarcoma
patients in a Danish nationwide, multi-centre, population-based study, in a recent period of
time (2000–2013), and furthermore to analyse the impact of the different comorbidities on
mortality.
Material and methods
The Danish population is 5.75 million [18]. All Danish residents are assigned a unique per-
sonal identification number (CPR number) and this facilitates the possibility of linking the
patient to all of the Danish registers [19]. Since 2011, treatment of sarcomas in Denmark has
been centralized in two centres in Aarhus and Copenhagen respectively. Until 2011, a centre
for treatment of soft tissue sarcoma also existed at Odense University Hospital. All patients
have been diagnosed and treated according to national guidelines by an experienced multidis-
ciplinary sarcoma team [20,21].
Data sources
The Danish Sarcoma Registry (DSR) is a national clinical database, administered by the Dan-
ish Sarcoma Group and supported by the Danish Regions [22]. All Danish patients with a
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newly diagnosed sarcoma in the extremities or trunk wall have been systematically registered
from January 1, 2009. Patients from 2000–2008 have recently been added based on a validation
through the Danish Cancer Registry (DCR) and the Danish National Pathology Registry
[23,24]. DSR contains patient characteristics and detailed data on tumour characteristics, treat-
ment, local and distant recurrences as well as death.
Information on comorbidities was obtained from the National Patient Registry (NPR) [25].
Since 1977, the NPR has recorded information on all hospital contacts including surgery,
pathology and diagnostic codes, as well as hospitalisation and discharge dates on an individual
level [26–28]. NPR covers more than 99% of all Danish hospital admissions [28]. Diagnoses
are classified based on the Danish version of the WHO International Classification of Diseases
(ICD); version 8 before 1994 and version 10 after.
Information on vital status was obtained from the Civil Registration System (CRS) estab-
lished in 1968. CRS is updated on a daily basis and contains CPR number, date of birth, vital
status, date of death or emigration for all residents of Denmark [19].
Causes of death were primarily accessed from the DSR and secondarily from the Cause of
Death Registry (CDR). The CDR was established in 1973 and registration is mandatory by law.
The registry contains information on the immediate and underlying causes of death on an
individual level [29].
By linking data from the DSR, the NPR, the CDR and the CRS we got information on age,
vital status, tumour information, patient characteristics (gender, age at diagnosis), treatment
(surgery, margin, radiation, chemotherapy), relapse, date and cause of death, and comorbidity.
Study population
A total of 3167 patients were treated at a Sarcoma Centre in Denmark between 2000–2013. We
included patients with sarcomas located in the extremities or trunk. Due to biological variation
patients aged 14 or less; borderline tumours; specific tumour subtypes, e.g., subcutaneous low-
grade liposarcoma/atypical lipomatous tumour; gastrointestinal stromal tumours (GIST); Kapo-
sis sarcoma; dermatofibrosarcoma protuberans; giant cell tumour; aggressive fibromatosis and
atypical fibroxanthoma were excluded. Thus, 2167 patients were included in the present study.
Comorbidity
Comorbidity was originally defined as any additional clinical event that existed or occurred
during the clinical course of a patient with an index disease during the study period [30]. How-
ever, in the present study, we only considered comorbidity prior to the diagnosis. To classify
the presence of comorbidity, we used the Charlson Comorbidity Index (CCI) [31]. It is based
on 19 different medical conditions, each weighted and assigned 1–6 points according to its
potential impact on mortality, derived from the relative risk estimates [31].
All discharge diagnoses included in the CCI were extracted from NPR for a period of 10
years prior to the date of the sarcoma diagnosis. Based on these, a CCI score was computed for
each patient. Tumours in soft tissue and bone (ICD-8; 170, 171, 192.49–99 and ICD-10; C40-
41, C47, C49) were not included. All discharge diagnoses of 30 days and all cancer diagnoses
of 90 days prior to the sarcoma diagnosis were excluded to eliminate surveillance bias and
diagnoses related to the sarcoma. The comorbidity level based on the CCI score was divided
into three groups: No comorbidity (score 0), mild comorbidity (score 1–2), and moderate/
severe comorbidity (score3).
Due to a low number of patients in many of the 19 CCI groups and thus insufficient statisti-
cal precision, we were not able to perform statistical analyses for each of the registered diseases.
Therefore, we merged the diagnoses from the original CCI into six comorbidity categories
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based on anatomical origin or organ system. We did not integrate the original CCI score in
these categories. The six categories were ‘No comorbidity’, ‘Cardiopulmonary disease’, ‘Gas-
trointestinal disease’, ‘Neurovascular disease’, ‘Malignant neoplasms’, and ‘Miscellaneous dis-
eases’ (diabetes with or without end organ damage, connective tissue disease and moderate/
severe renal disease). The six comorbidity categories are shown in Table 1 and all correspond-
ing ICD-8 and ICD-10-codes are available in S1 Table.
Mortality
Mortality was assessed using overall and disease-specific mortality. Follow-up time was from
the date of their sarcoma diagnosis until death, emigration, or end of study period (June 22,
2016). Disease-specific mortality was defined as death from sarcoma or death with known met-
astatic disease (ICD-8; 170, 171, 192.49–99 and ICD-10; C40-41, C47, C49).
Statistical analysis
Descriptive statistics were used for the prevalence of comorbidity. Chi-squared test was used
to compare the distribution of comorbidity between patient and tumour characteristics. In
Table 1. Charlson comorbidity index, number of patients in each comorbidity category and matching scores for
the 19 medical conditions.
Comorbidity Categories: CCI score: N (%)
No Comorbidity 0 1.741 (80.3)
Cardiopulmonary disease: 60 (2.3)
Myocardial infarction 1
Congestive heart failure 1
Chronic pulmonary disease 1
Gastrointestinal disease: 18 (0.8)
Ulcer disease 1
Mild liver disease 1
Moderate/severe liver disease 3
Neurovascular disease: 57 (2.6)
Peripheral vascular disease 1
Cerebrovascular disease 1
Dementia 1
Hemiplegia 2
Malignant neoplasms: 196 (9.0)
Any tumour  2
Leukaemia 2
Lymphoma 2
Metastatic solid tumour 6
Miscellaneous diseases: 95 (4.4)
Connective tissue disease 1
Diabetes 1
Moderate/severe renal disease 2
Diabetes with end organ damage 2
AIDS 6
CCI: Charlson Comorbidity Index; AIDS: acquired immunodeficiency syndrome.
 Excluding tumours in soft tissue and bone (iCD-8; 170, 171, 192.49–99 and iCD-10; C40-C41, C47, C49).
https://doi.org/10.1371/journal.pone.0198933.t001
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order to minimize bias we used causal directed acyclic graphs (DAGs) (S1 Fig) to select rele-
vant covariates for the multiple regression model [32]. We adjusted for age, which is highly
associated to comorbidity and a strong predictor of mortality [7–14]. Overall mortality was
estimated using the Kaplan-Meier method. A Cox proportional hazard model was used to
compute crude and adjusted hazard ratios (HR) for overall mortality. Because of dependent
events, cumulative incidence was estimated for disease-specific mortality, treating death of
other causes than sarcoma as a competing risk [33]. Multivariate competing risk regression
analyses were used for both crude and adjusted disease-specific mortality [34]. Patients with
‘No comorbidity’ served as the reference group in both analyses. Effect modification was tested
using likelihood ratio test. All test were two-sided and a p-value <0.05 was considered statisti-
cally significant. Estimates were made with corresponding 95% confidence intervals (CI). All
analyses were performed in STATA 13.1 software.
Ethics
The Danish Data Protection Agency (j.nr: 1-16-02-245-14), Statens Serum Institute (FSEID-
1729) and the Danish Clinical Registries (j.nr: DSD-2017-03-02) approved this study.
Results
Patient characteristics and prevalence of comorbidity
The characteristics of the 2167 included patients are shown in Table 2 in relation to the CCI-
score and in relation to the comorbidity categories. Of these, 1906 (88%) had localized disease
at time of diagnosis. The median age at diagnosis was 56 years and 55% of the patients were
men. Median follow-up time was 5.5 years (range 0.0–16.1 years). Most patients (88%)
received surgery, 20% received radiotherapy and 12% chemotherapy as part of primary treat-
ment. In total, 426 (20%) patients had registered comorbidity at the time of diagnosis (19% of
patients with localized disease and 28% of patients with metastases). Moderate/severe comor-
bidity was found in 275 (13%) patients, mild comorbidity in 151 (7%) patients, and no comor-
bidity in 1741 (80%) patients. The largest comorbidity category was malignant neoplasms with
196 (9%) patients. The group of miscellaneous diseases consisted of 95 patients, where 65%
had diabetes with or without end organ damage, 18% connective tissue disease and 16% mod-
erate/severe renal disease. Table 1 shows the distribution of patients for each comorbidity
category.
Overall mortality
For patients with localized disease at the time of diagnosis, the one- and five-year overall mor-
tality was 8% (95% CI 7–10) and 32% (95% CI 30–34), respectively. For patients with meta-
static disease, the one- and five-year overall mortality was 50% (95% CI 44–56) and 83% (95%
CI 30–34), respectively. The overall mortality for comorbidity vs. no comorbidity is shown in
Fig 1A and 1B.
Mortality significantly increased in patients with comorbidity and localized disease at the
time of diagnosis, with a crude HR of 1.89 (95% CI 1.59–2.25) compared to patients without
comorbidity. Mortality did not differ for comorbidity vs. no comorbidity in patients with met-
astatic disease at the time of diagnosis (crude HR: 1.05 (95% CI 0.78–1.42)).
As seen in Table 3, the adjusted overall mortality was significantly higher in the comorbid-
ity categories gastrointestinal disease, malignant neoplasms, and miscellaneous diseases.
There was no association between type of comorbidity and mortality for patients with met-
astatic disease at time of diagnosis.
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Disease-specific mortality
A total of 631 (29%) patients died from sarcoma. For patients with localized disease, the one-
and five-year disease-specific mortality was 6% (95% CI 5–7) and 23% (95% CI 21–25), respec-
tively. For patients with metastatic disease, the one- and five-year disease-specific mortality
was 48% (95% CI 42–55) and 81% (95% CI 75–86), respectively. Cumulative incidence curves
of disease-specific mortality are shown in Fig 1C and 1D. For patients with localized disease,
disease-specific mortality significantly increased in the presence of comorbidity (70% increase
in mortality rate (95% CI 1.36–2.13)). For patients with metastatic disease at the time of diag-
nosis, comorbidity did not affect the disease-specific mortality (5% increase in mortality rate
(95% CI 0.78–1.42)). The crude disease-specific mortality was significantly higher in the
comorbidity categories malignant neoplasms (90% increase in mortality rate (95% CI 1.41–
2.57)) and miscellaneous diseases (78% increase in mortality rate (95% CI 1.17–2.69)), as seen
in Table 3. Adjusting for age, the presence of another cancer diagnosis within ten years prior
Table 2. Patient characteristics (N: 2167) by Charlson comorbidity index score and by comorbidity categories.
N (%) Charlson Comorbidity Index
Score N (%)
Comorbidity Categories N(%)
0 1–2 3 Cardiopulmonary Gastrointestinal Neurovascular Mal. neoplasms Miscellaneous
Total 2167
(100)
1741 (80) 151 (7) 275 (13) 60 (3) 18 (1) 57 (3) 196 (9) 95 (4)
Age (years)
Median (range) 56 (15–
96)
54 (15–
96)
64 (17–
93)
66 (16–
93)
61 (12–82) 71 (43–93) 68 (19–93) 54 (16–91) 66 (26–90)
15–49 759 (35) 697 (40) 21 (14) 41 (15) 11 (18) 1 (6) 5 (9) 32 (16) 13 (14)
50–69 823 (38) 648 (37) 66 (44) 109 (40) 25 (42) 7 (39) 23 (40) 82 (42) 38 (40)
70 584 (27) 395 (23) 64 (42) 125 (45) 24 (40) 10 (56) 29 (51) 82 (42) 44 (46)
Sex
Female 972 (45) 776 (45) 63 (42) 133 (48) 20 (33) 8 (44) 21 (37) 102 (52) 45 (47)
Male 1195 (55) 965 (55) 88 (58) 142 (52) 40 (67) 10 (56) 36 (63) 94 (48) 50 (53)
Stage at diagnosis
Localized 1906 (88) 1553 (89) 132 (87) 221 (80) 54 (90) 16 (89) 48 (84) 154 (79) 81 (85)
Metastatic 261 (12) 188 (11) 19 (13) 54 (20) 6 (10) 2 (11) 9 (16) 42 (21) 14 (15)
Tumour size (cm)
Median (range) 8.9 (1–52) 9.0 (1–52) 8.7 (1–40) 8.4 (1–30) 7.8 (1–25) 7.9 (1–30) 8.8 (1–40) 8.6 (1–29) 8.6 (1–25)
Location
Subcutaneous 630 (33) 510 (33) 41 (32) 79 (35) 15 (29) 6 (38) 19 (37) 49 (31) 31 (40)
Subfascial 1261 (67) 1027 (67) 87 (68) 147 (65) 37 (71) 10 (63) 33 (63) 107 (68) 47 (60)
Malignancy grade
Low 509 (26) 434 (27) 29 (21) 46 (19) 11 (20) 1 (8) 13 (24) 31 (18) 19 (22)
Intermediate 399 (20) 325 (20) 31 (22) 43 (18) 11 (20) 5 (38) 10 (19) 31 (18) 17 (20)
High 1083 (54) 853 (53) 79 (57) 151 (63) 34 (60) 7 (54) 31 (57) 107 (63) 51 (59)
Treatment
Surgery 1913 (88) 1555 (89) 128 (85) 230 (84) 50 (83) 13 (72) 50 (88) 161 (82) 84 (88)
Wide/radical 993 (41) 817 (60) 63 (57) 113 (56) 27 (60) 7 (70) 24 (57) 78 (57) 40 (51)
Intralesional/
marginal
689 (59) 551 (40) 48 (43) 90 (44) 18 (40) 3 (30) 18 (43) 60 (43) 39 (49)
Radiotherapy 429 (20) 345 (20) 32 (21) 52 (19) 16 (27) 4 (22) 8 (14) 40 (20) 16 (17)
Chemoterapy 264 (12) 218 (13) 15 (10) 31 (11) 7 (12) 1 (6) 3 (5) 26 (13) 9 (9)
Notes: N: number. Mal.: Malignant. I Tumour size: 309 missing. Grade: 176 missing.
https://doi.org/10.1371/journal.pone.0198933.t002
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to the sarcoma diagnosis was the only significant independent prognostic factor of disease-spe-
cific mortality with a 66% increase in mortality level (95% CI 1.22–2.25) compared to patients
with no comorbidity.
Among patients with metastatic disease at the time of diagnosis, there was no significant
difference in disease-specific mortality for different comorbidity categories.
Discussion
In this nationwide, population-based study of 2167 sarcoma patients, we found an overall
prevalence of comorbidity of 20% based on the CCI. The level of comorbidity had a significant
negative impact in both overall and disease-specific mortality in patients with localized disease
at the time of diagnosis. This suggests that the survival is modifiable in the group of patients
with comorbidity and that an early intervention could change the prognosis. Especially among
those with a previous cancer diagnosis, who had a 66% greater risk of dying from their sar-
coma than patients without comorbidity. No impact of comorbidity on mortality was found in
patients with metastatic sarcoma.
Methodological considerations
The strengths of this study include the population-based design, the use of reliable national
registries, and the homogeneous healthcare provided in Denmark. We had a relatively large
sample size in a limited time period, and long-term follow-up. This ensured a high statistical
precision.
The DSR contains data on treatment, follow-up, and vital status for all sarcoma patients in
Denmark, which prevented selection bias. The study included all patients treated in a defined
Fig 1. Estimates of impact of comorbidity on overall mortality and disease-specific mortality. Kaplan-Meier
estimates of the impact of comorbidity on overall mortality for patients with (A) localized disease and (B) metastatic
disease. Cumulative incidence curves of the impact of comorbidity in disease-specific mortality in (C) localized disease
and (D) metastatic disease.
https://doi.org/10.1371/journal.pone.0198933.g001
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and recent time period and thus the group of patients can be considered homogenous regard-
ing the diagnostic evaluation process and treatment. Information bias from the administrative
registries NPR, CDR, and CRS is low. Still, the data in the national registries depends on the
correctness of the physicians when the medical records are filled in. The comorbidity diagno-
ses were recorded in a 10-year period before the sarcoma diagnosis, and thus, any misclassifi-
cation is non-differential. A review of 950 medical records to verify the NPR diagnoses using
ICD-10 codes found a positive predictive value of 98% for the CCI conditions [35].
The limitations of this study include the risk of differential misclassification of the cause of
death by using registries such as the CDR. If the patient dies in close temporal proximity to the
sarcoma diagnosis or treatment; there will be an inclination to state the sarcoma as cause of death.
Using the CCI to assess the level of comorbidity in cancers is common, and has been vali-
dated several times [8,11,13,36]. Only hospital-based diagnoses of comorbidity were registered
in this study. Thus, there is a probability of underestimating some of the mild conditions in
the NPR, as these are mainly treated in primary care.
The comorbidities were categorised based on anatomical origin or affected organ system.
Both mild and severe diseases were pooled in the same comorbidity categories. This may have
lowered the detailed information about the specific comorbidities in question, but the statisti-
cal precision increased considerably. We pooled patients with both soft tissue and bone sarco-
mas in relation to comorbidity and mortality, although the variation in biological manners,
distribution of age, and treatment is different to some extend. Finally, no data on life style fac-
tors such as smoking, body mass index, and use of alcohol or medication was provided, all of
which factors that possibly affects the mortality rate.
Table 3. Crude and adjusted analyses for the association between type of comorbidity, and the overall and disease-specific mortality in patients with localized and
metastatic disease respectively (n = 2167).
Overall mortality Disease-specific mortality
HR (95% CI) HR (95% CI)
N 1-year (%) 5-year (%) Crude Adjusted 1-year (%) 5-year (%) Crude Adjusted
Total 2167
Localized
Overall 1906 8 32 6 23
No comorbidity 1553 7 29 1 1 4 20 1 1
Cardiopulmonary 54 13 39 1.48 (0.97–2.25) 1.21 (0.80–1.84) 6 26 1.52 (0.91–2.55) 1.36 (0.81–2.28)
Gastrointestinal 16 31 68 3.14 (1.72–5.70) 1.86 (1.02–3.40) 13 34 2.11 (0.87–2.07) 1.64 (0.67–3.98)
Neurovascular 18 13 49 1.99 (1.31–3.02) 1.33 (0.87–2.02) 6 20 1.02 (0.51–2.07) 0.84 (0.41–1.70)
Malignant neoplasm 154 16 45 1.83 (1.44–2.34) 1.41 (1.10–1.80) 13 31 1.90 (1.41–2.57) 1.66 (1.22–2.25)
Miscellaneous 81 14 48 2.85 (1.50–2.81) 1.48 (1.07–2.03) 11 31 1.78 (1.17–2.69) 1.51 (0.99–2.30)
Metastatic
Overall 261 50 83 48 81
No comorbidity 188 47 84 1 1 45 78 1 1
Cardiopulmonary 6 50 - 0.84 (0.31–2.26) 0.69 (0.25–1.86) 50 71 0.91 (0.34–2.46) 0.75 (0.27–2.03)
Gastrointestinal 2 50 - 1.16 (0.29–4.69) 0.76 (0.18–3.26) - 60 0.63 (0.09–4.53) 0.43 (0.06–3.20)
Neurovascular 9 78 78 1.61 (0.76–3.45) 1.23 (0.57–2.66) 67 66 1.50 (0.66–3.40) 1.15 (0.50–2.64)
Malignant neoplasm 42 60 79 1.01 (0.70–1.47) 0.82 (0.56–1.22) 57 76 1.07 (0.73–1.56) 0.87 (0.59–1.30)
Miscellaneous 14 43 - 1.02 (0.57–1.84) 0.91 (0.51–1.65) 43 80 1.01 (0.55–1.86) 0.90 (0.49–1.67)
CI: confidence interval; HR: hazard ratio; N: number.
 Analyses adjusted for age.
 Diabetes with or without end organ damage, connective tissue disease, and moderate/severe renal disease
https://doi.org/10.1371/journal.pone.0198933.t003
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Comparison with other studies
The 20% prevalence of comorbidity in this nationwide study is in concordance with the few
previous studies in sarcoma patients, which found a 19% prevalence of comorbidity in bone
sarcoma patients and 25% of soft tissue sarcoma patients [16,37]. These studies were single
centre retrospective studies with a span of 30 years. 5-year disease-specific mortality was 26%
for soft tissue sarcoma patients without comorbidity and 33% to 44% for patients with mild to
severe comorbidity. Compared to our findings there is a considerable difference in disease-
specific survival both in the group of patients with no comorbidity as well as patients with
comorbidity. This could be due to the extensive progress in diagnosis and treatment and
advancements in diagnostic imagining and evaluation of surgical materials the last decades.
Greater accessibility to CT scan, the emergence of MRI scan and the increased use of ultra-
sound might have diminished the diagnostic window [17]. New forms of chemotherapy, prog-
ress in surgical techniques including focus on wide resection, and the implementation of the
urgent fast-track referral pathway in Denmark in January 2009 could all be underlying reasons
for improved outcome [17,38]. Furthermore, in this present study we found that gastrointesti-
nal disease, malignant neoplasms, and miscellaneous diseases had significant impact on overall
mortality, while a preceding cancer diagnose had significantly impact on disease-specific mor-
tality. A sarcoma-specific comorbidity index was the ideal outcome of this study in order to
identify specific diseases, but the representation of the different 19 diseases in the study popu-
lation was unfortunately not large enough. Still, the comorbidity categories might imply where
special attention should be made in order to improve the outcome for sarcoma patients with
comorbidity. Other studies have reported a prevalence of comorbidity in soft tissue sarcoma
patients at 12%; however, this was at the time of diagnosis, and did not include discharge diag-
noses in a 10-year period before diagnosis [39].
Several studies have investigated the prevalence of comorbidity according to the CCI in
other cancers such as prostate (37%), ovarian (24%), colorectal (14–34%), breast (13–20%),
lung (50%), and head and neck cancer (33%) [9,11,12,14,40–42]. In general, the proportion of
patients with comorbidity is greater in other cancers. This could be due to a relatively low
median age of 56 years and a considerable group of younger patients among the bone sarco-
mas [39]. It could also be due to aetiological factors, e.g., smoking in lung cancer and smoking
and alcohol abuse in head and neck cancer [9,11].
The prevalence of comorbidity in sarcoma patients seems to reflect the comorbidity of the
general population. This is supported by studies, where prevalence of comorbidity according
to the 19 CCI conditions in soft tissue sarcoma patients and an age- and sex-matched cohort
was comparable, except for ‘any tumour’ and ‘metastatic solid tumour’ [43]. According to a
UK retrospective study of 287,459 primary care patients, 26.5% of the patients had comorbid-
ity according to the diagnoses in the CCI. The prevalence of comorbidity was 14% as calculated
from the diagnoses within the CCI in 21,868 age-matched controls in a study with 5,192 breast,
lung, colon, prostate and ovarian cancer patients [44].
We found that the presence of comorbidity had a significant impact on both overall and
disease-specific mortality in patients with localized disease at the time of diagnosis. This is in
concordance with previous findings in studies of soft tissue sarcomas [16]. Studies in bone sar-
comas have shown that comorbidity was a strong independent prognostic factor on overall
survival but not on disease-specific mortality [37]. The impact of comorbidity on cancer sur-
vival has been investigated in other cancers. In head and neck cancer, comorbidity was a
strong independent prognostic factor on overall survival, but not for cancer-specific death
[11]. Studies of breast cancer show that the presence of comorbidity had a strong independent
effect on both disease-specific and overall survival [45,46].
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In patients with metastatic disease at the time of diagnosis, we found that comorbidity did
not have an impact on mortality. This is most probably due to the poorer prognosis of a meta-
static cancer.
Comorbidity may mask early cancer symptoms leading to delay and therefore a more
advanced stage of the disease at time of diagnosis. However, other studies have found a higher
prevalence of comorbidity in early-stage cancers [9,45]. An explanation could be that patients
receiving more frequent medical care due to their comorbidity are more likely to receive clini-
cal monitoring.
Surgery with wide margins is the primary curative treatment of soft tissue sarcomas and
bone sarcomas, alone or in a combination with radiotherapy and/or chemotherapy [5]. Cer-
tain comorbidities and associated medical treatments may serve as an absolute or relative con-
traindication for optimal treatment. This may affirm the influence of comorbidity on
mortality as seen in our study.
Conclusion
In this nationwide, population-based study, we found a prevalence of comorbidity of 20% of
sarcoma patients. The comorbidity categories gastrointestinal disease, malignant neoplasms,
and miscellaneous diseases had significant independent influence on overall mortality. Dis-
ease-specific mortality was affected only by a preceding cancer diagnose.
The presence of comorbidity was a strong independent prognostic factor on overall as well
as disease-specific mortality in patients with localized disease but not among patients with
metastases at the time of diagnosis. The study emphasizes the need for improving the general
health of patients with comorbidity in order to gain a survival benefit from treatment of
patients with localized disease, as this is potentially modifiable.
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